Literature DB >> 30128858

Reproductive and gynecological complication risks among thyroid cancer survivors.

Brenna E Blackburn1,2, Patricia A Ganz3, Kerry Rowe4, John Snyder4, Yuan Wan5, Vikrant Deshmukh6, Michael Newman1,6, Alison Fraser5, Ken Smith5, Kimberley Herget7, Jaewhan Kim8, Anne C Kirchhoff2,9, Christina Porucznik1, Heidi Hanson1,5, Dev Abraham10, Marcus Monroe2,11, Mia Hashibe12,13.   

Abstract

PURPOSE: Thyroid cancer is the most rapidly increasing cancer in the USA, affects a young, mostly female population, and has high survival. The aim of this study was to determine if there is an increased risk of reproductive system adverse events or pregnancy complications among women diagnosed with thyroid cancer under the age of 50.
METHODS: Up to five female cancer-free individuals were matched to each female thyroid cancer survivor diagnosed before the age of 50 based on birth year, birth state, and follow-up time, within the Utah Population Database. Medical records were used to identify disease diagnoses stratified over three time periods: 0-1, > 1-5, and > 5-10 years after cancer diagnosis. Cox proportional hazards models were used to estimate hazard ratios (HR) with adjustment on matching factors, race, BMI, and Charlson Comorbidity Index.
RESULTS: There were 1832 thyroid cancer survivors and 7921 matched individuals. Thyroid cancer survivors had higher rates of having multiple health conditions associated with the gynecological system (15.4% vs. 9.4%) and pregnancy (14.3% vs 9.5%) > 1-5 years after cancer diagnosis. Increased risks persisted > 5-10 years after cancer diagnosis for menopausal disorders (HR = 1.78, 99% CI = 1.37, 2.33) and complications related to pregnancy (HR = 2.13, 99% CI = 1.14, 3.98). Stratified analyses showed these risks remained increased across different treatment types.
CONCLUSIONS: There were significant risk increases in reproductive system and pregnancy complications among female thyroid cancer survivors within this study. IMPLICATIONS FOR CANCER SURVIVORS: Although radiation has been linked to reproductive risks in previous studies, we found risks were increased in patients regardless of treatment.

Entities:  

Keywords:  Gynecological risks; Pregnancy complications; Reproductive risks; Thyroid cancer survivors

Mesh:

Year:  2018        PMID: 30128858      PMCID: PMC6158013          DOI: 10.1007/s11764-018-0707-7

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.442


  16 in total

1.  Radioiodine therapy and age at menopause in patients with thyroid cancer.

Authors:  Pedro Weslley Souza Rosario; Tales Alvarenga Fagundes; Aranai Villasboas Fagundes; Alvero Luis Barraso; Leonardo Lamego Rezende; Eduardo Lanza Padrao; Valeria C Guimaraes; Saulo Purisch
Journal:  Clin Endocrinol (Oxf)       Date:  2006-02       Impact factor: 3.478

2.  Results of the Thyroid Cancer Alliance international patient/survivor survey: Psychosocial/informational support needs, treatment side effects and international differences in care.

Authors:  Rita Banach; Beate Bartès; Kate Farnell; Harald Rimmele; Joan Shey; Susanne Singer; Frederik A Verburg; Markus Luster
Journal:  Hormones (Athens)       Date:  2013 Jul-Sep       Impact factor: 2.885

Review 3.  Effects of I-131 therapy on gonads and pregnancy outcome in patients with thyroid cancer.

Authors:  Chrissa Sioka; Andreas Fotopoulos
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Menstrual cycle disorders after therapy with iodine-131.

Authors:  Chrissa Sioka; Gregory Kouraklis; Athanasios Zafirakis; Angeliki Manetou; Nikolaos Dimakopoulos
Journal:  Fertil Steril       Date:  2006-06-16       Impact factor: 7.329

6.  Ovarian function after radioiodine therapy in patients with thyroid cancer.

Authors:  P W Souza Rosário; T Alvarenga Fagundes; A S Villas-Boas Fagundes; A L Barroso; L Lamego Rezende; E Lanza Padrão; V C Guimarães; A C Horta; M Franco; S Purisch
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-06       Impact factor: 2.949

7.  Maternal obesity, gestational hypertension, and preterm delivery.

Authors:  Juliette Madan; Minghua Chen; Elizabeth Goodman; Jonathan Davis; Walter Allan; Olaf Dammann
Journal:  J Matern Fetal Neonatal Med       Date:  2010-01

Review 8.  A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors.

Authors:  Anna M Sawka; Deepak C Lakra; Jane Lea; Bandar Alshehri; Richard W Tsang; James D Brierley; Sharon Straus; Lehana Thabane; Amiram Gafni; Shereen Ezzat; Susan R George; David P Goldstein
Journal:  Clin Endocrinol (Oxf)       Date:  2008-02-13       Impact factor: 3.478

Review 9.  Controversies in primary treatment of low-risk papillary thyroid cancer.

Authors:  Donald S A McLeod; Anna M Sawka; David S Cooper
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

10.  Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies.

Authors:  Jie Ma; Min Huang; Li Wang; Wei Ye; Yan Tong; Hanmin Wang
Journal:  Med Sci Monit       Date:  2015-01-22
View more
  2 in total

1.  Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.

Authors:  Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves
Journal:  J Cancer Surviv       Date:  2020-06-06       Impact factor: 4.442

Review 2.  Risk of Adverse Pregnancy Outcomes in Young Women with Thyroid Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shinje Moon; Ka Hee Yi; Young Joo Park
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.